Alnylam Pharmaceuticals Inc. Appoints New Chief R&D Officer and Hits All-Time Stock High

Alnylam Pharmaceuticals, Inc., a leading biotechnology company specializing in RNA interference (RNAi) therapeutics, has recently made significant strides both in leadership and market performance. Based in Cambridge, Massachusetts, Alnylam is known for its innovative approach to developing drugs for treating human diseases, with a focus on delivering transformative RNAi therapeutics.

On June 18, 2025, Alnylam announced the appointment of Pushkal Garg, M.D., as the Executive Vice President and Chief Research and Development Officer. This strategic move aims to enhance the company’s R&D capabilities by integrating its research and development organization. Garg’s appointment is expected to accelerate the progress of Alnylam’s pipeline by fostering earlier collaboration, faster decision-making, and more agile responses to scientific opportunities and patient needs. Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam, expressed her excitement about Garg’s leadership, highlighting his strategic vision and operational excellence. Under his guidance, Alnylam aims to deliver RNAi therapeutics to all major tissues by 2030.

In addition to the leadership change, Alnylam Pharmaceuticals’ stock reached an all-time high of $311.24 on the same day. This milestone reflects investor confidence in the company’s growth trajectory and its recent achievements, including the launch of AMVUTTRA® for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The company’s market capitalization stands at $39.73 billion, with a close price of $308.71 as of June 16, 2025. Despite a negative price-to-earnings ratio of -145.58, the stock’s performance indicates strong market sentiment.

Alnylam’s recent advancements and strategic leadership changes position the company for continued growth in the biotechnology sector. With a focus on innovation and patient-centric drug development, Alnylam is poised to make significant contributions to the healthcare industry in the coming years.